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Apicomplexa  are  unicellular  eukaryotes  that 
multiply intracellularly in their hosts. They in-
clude parasites of major medical importance like 
Plasmodium species, the causative agent of ma-
laria,  and  Toxoplasma  gondii,  an  opportunistic 
parasite of immunosuppressed individuals and a 
cause of congenital disease. In the mammalian 
host, Plasmodium differentiate and multiply in-
side host erythrocytes, whereas in the inter-
mediate host, T. gondii alternates between two 
developmental forms: the tachyzoite, the prolif-
erative form that rapidly divides and disseminates 
in the host, and the bradyzoite, the cystic form 
responsible for persistence in host tissues (1-3).
Stage conversion in Apicomplexa is associ-
ated with global modifications of mRNA con-
tents, suggesting that developmental switches 
are transcriptionally regulated (4-6). The mech-
anisms by which Apicomplexa regulate expres-
sion of their genes are still poorly understood. 
They lack many of the typical eukaryotic tran-
scription factors, with one exception being the 
plant-like AP2 DNA binding family, the major 
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Plasmodium and Toxoplasma are parasites of major medical importance that belong to the 
Apicomplexa phylum of protozoa. These parasites transform into various stages during their 
life cycle and express a specific set of proteins at each stage. Although little is yet known 
of how gene expression is controlled in Apicomplexa, histone modifications, particularly 
acetylation, are emerging as key regulators of parasite differentiation and stage conversion. 
We investigated the anti-Apicomplexa effect of FR235222, a histone deacetylase inhibitor 
(HDACi). We show that FR235222 is active against a variety of Apicomplexa genera, 
including Plasmodium and Toxoplasma, and is more potent than other HDACi’s such as 
trichostatin A and the clinically relevant compound pyrimethamine. We identify T. gondii 
HDAC3 (TgHDAC3) as the target of FR235222 in Toxoplasma tachyzoites and demonstrate 
the crucial role of the conserved and Apicomplexa HDAC-specific residue TgHDAC3 T99 in 
the inhibitory activity of the drug. We also show that FR235222 induces differentiation of 
the tachyzoite (replicative) into the bradyzoite (nonreplicative) stage. Additionally, via its 
anti-TgHDAC3 activity, FR235222 influences the expression of 370 genes, a third of 
which are stage-specifically expressed. These results identify FR235222 as a potent HDACi 
of Apicomplexa, and establish HDAC3 as a central regulator of gene expression and stage 
conversion in Toxoplasma and, likely, other Apicomplexa.
© 2009 Bougdour et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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molar concentrations (EC50 ≈ 10 nM; Fig. 1 A and Table I). 
In contrast, hydroxamic acid HDACi compounds (tricho-
statin A [TSA] and Scriptaid), which affect human cell prolif-
eration  by  inducing  cell-cycle  arrest  and/or  stimulating 
apoptosis of certain cancer cells, were less efficient in inhibit-
ing T. gondii proliferation (EC50 = 400 nM; Fig. 1 A). Note 
that cyclopeptide HDACi’s more efficiently inhibit T. gondii 
growth  than  pyrimethamine  (pyrimethamine  EC50  =  300 
nM; Fig. 1 A and Table I), a compound currently used clini-
cally. FR235222 displayed comparable effects on T. gondii 
types I (RH), II (Prugniaud), and III (CTG), as well as on 
Neospora  caninum,  a  closely  related  Apicomplexan  parasite 
(Fig. 1 B). Low nanmolar concentrations of FR235222 also 
inhibited  Plasmodium  intraerythrocytic  cycle  in  vitro.  It  is 
noteworthy that FR235222 EC50s are equivalent on P. falci-
parum 3D7 and Dd2 clones, which are sensitive and resistant, 
respectively, to the chloroquine (Fig. 1 C).
FR235222 treatment also blocked the development of 
synchronized P. berghei cultures from the ring to the tropho-
zoite stages, and from the trophozoite to the schizont stages, 
although  schizonts  were  somewhat  less  sensitive  to  drug 
treatment (Fig. 1 D and not depicted).
Histone H4 hyperacetylation in FR235222-treated T. gondii
T.  gondii  multiplies  intracellularly  by  endodyogeny.  Anti-
bodies directed against the inner membrane complex protein 
1 (IMC1) allow monitoring of the formation of the internal 
daughter cells inside the parental dividing parasites (Fig. 1 E).   
Unlike parasites grown in the absence of drug, intracellu-
lar  parasites  treated  with  FR235222  were  vacuolated  and 
lacked IMC1-delineated daughter cells, or contained aber-
rant progeny (Fig.1 E, arrowhead). Also, the majority of the 
drug-treated parasites (80%) displayed massive DNA over-
replication  (>1N  DNA  content  per  cell),  indicating  that   
FR235222 interferes directly or indirectly with T. gondii 
cell-cycle progression.
To confirm the anti-HDAC activity of FR235222 (16-18) 
on T. gondii, the nuclei of FR235222-treated parasites were 
stained using antibodies directed against acetylated histone 
H4 (AcH4; Fig. 1 E and Fig. S1). As expected, AcH4 signals 
were higher in the nuclei of treated parasites than with the 
DMSO control. The increase in AcH4 signals as well as the 
DNA overreplication were not observed in parasites treated 
with pyrimethamine (non-HDACi compound; inhibitor of 
the dihydrofolate reductase) nor in the hxgprt RH parasites 
treated with mycophenolic acid and xanthine (non-HDACi 
compound; inhibitor of guanine nucleotide synthesis path-
way; Fig. S1), indicating that histone hyperacetylation and 
the abnormal cell cycle were specifically caused by FR235222 
and were not the consequence of dying parasites.
To ascertain that the drug acted directly on the parasites, 
and not via host cells, extracellular tachyzoites were incu-
bated in the presence of the drug and histone H4 acetylation 
levels were analyzed by immunoblotting (Fig. 1 F). The AcH4 
signals increased approximately eightfold in the FR235222-
treated parasites, confirming that the drug induces histone 
lineage-specific expansion of transcriptional regulators in the 
phylum (7). In contrast, these parasites possess a rich repertoire 
of enzymes involved in histone modification and chromatin 
remodeling (8). This suggests that Apicomplexa may be un-
usually reliant on epigenetic mechanisms to control develop-
mental gene expression and cellular identity (2, 8).
In yeast and metazoa, acetylases and histone deacetylases 
(HDACs) play a major role in controlling gene expression by 
switching between the acetylated and deacetylated states of 
chromatin (9). In T. gondii, histone acetylation affects gene 
expression (10, 11) and correlates with tachyzoite to bradyzo-
ite  differentiation  (11),  and  HDAC  inhibitors  (HDACi’s) 
modify  the  abundance  of  developmentally  regulated  gene 
transcripts (12). Thus, acetylases and HDACs likely play an 
important role in the control of stage-specific gene expression 
during parasite differentiation.
The effect of HDACi’s on Apicomplexa has been previ-
ously documented with the discovery of apicidin, a cyclic 
tetrapeptide having broad-spectrum antiparasitic activity (13). 
Despite this promising discovery, the mechanism of action of 
apicidin against Apicomplexa has not been documented so 
far. To date, various HDACi’s have been isolated, and each 
chemical compound displays different properties in terms of 
the class of HDAC inhibited and downstream cellular effect 
on human cell lines (14, 15).
In this work, we examined the effect and investigated the 
mode of action of FR235222, a novel cyclic tetrapeptide 
HDACi isolated from the fermentation broth of Acremonium 
species (16). We first show that the drug is active against a 
wide range of Apicomplexa, blocks the growth and differen-
tiation of P. falciparum and berghei parasites in red blood cells, 
and induces T. gondii tachyzoite to bradyzoite differentiation. 
Using a genetic approach, we identify HDAC3 as the target 
of the drug in T. gondii, and show that the drug inhibitory ac-
tivity depends on a two-residue insertion within the catalytic 
site of the enzyme (A98T99 in T. gondii HDAC3 [TgH-
DAC3]), which is present exclusively in the HDAC3 family 
of proteins in Apicomplexa and is absent from any other 
HDAC identified so far in other organisms. Finally, using 
chromatin immunoprecipitation (ChIP) combined with DNA 
microarray (ChIP-on-chip) assays, we identify 369 Toxoplasma 
gene upstream regions containing hyperacetylated nucleo-
somes upon FR235222 treatment, one third of which are 
mainly expressed in the sporozoite and/or bradyzoite stage of 
parasite. Collectively, our results confirm that histone acetyla-
tion plays a significative role in the control of parasite differ-
entiation and that TgHDAC3 is a regulator acting within the 
regulatory pathway leading to parasite differentiation.
RESULTS
FR235222 is an efficient inhibitor of the intracellular 
multiplication of Apicomplexa parasites
We first assessed the effect of FR235222 on the growth of T. 
gondii in human foreskin fibroblasts (HFFs). FR235222 and 
the other cyclopeptide HDACi’s, such as HC-toxin and api-
cidin, inhibited T. gondii intracellular growth at low nano-JEM VOL. 206, April 13, 2009 
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Figure 1.  In vitro antiprotozoal activity of FR235222 and other HDACi’s. In vitro inhibitory concentrations for FR235222 and other compounds 
against Apicomplexan parasite growth were determined by measuring the incorporation of [3H]uracil by intracellular T. gondii tachyzoites and of 
[3H]thymidine by Plasmodium species, as described in Materials and methods. (A) Effect of FR235222 and other HDACi’s on T. gondii RH strain growth in 
HFF monolayer. Pyrimethamine (non-HDACi compound) was used as a clinically relevant control. Means ± SD of parasite growth (percentages) are 
shown (n = 3 experiments). (B) Effect of FR235222 on N. caninum; T. gondii types I (RH), II (Pru), and III (CTG) wild-type strains; and the type I 
FR235222-resistant mutant M190D4. The data are plotted as the percentage of the control in the absence of drug. Means ± SD of parasite growth (per-
centages) are shown (n = 3 experiments). (C) Effects of FR235222 on P. falciparum clones 3D7 and Dd2. Effectiveness of FR235222 was compared with 
Chloroquine. EC50 values are plotted. Means ± SD of EC50 (nanomolar) are shown (n = 4 experiments for each set of data). (D) Effect of FR235222 on 
P. berghei blood stage development. Intraerythrocyte P. berghei GFP@hsp70 ANKA parasites were synchronized as described in Materials and methods. 
Synchronized in vitro cultures were treated with 54 nM FR235222 after 5, 11, and 22 h of intracellular growth. The development of the parasites was 
assessed at the indicated time points by Giemsa staining. Bars, 8 µm. (E) Effects of FR235222 on histone H4 acetylation in intracellular T. gondii para-
sites. Confluent monolayers of HFF cells were infected with T. gondii RH WT and R20D9 (TgHDAC3T99A) strains in the presence of 40 nM FR235222 and 
0.1% DMSO as a control. As a control, parasites were treated with 1 µM pyrimethamine. After 24 h of growth, cells were fixed and stained for AcH4 
(red) and IMC1 (green). The arrowhead indicates aberrant progeny. A representative set of data is shown. Bars, 5 µm. (F) Extracellular T. gondii parasites 
(RH WT, R20D9 [TgHDAC3T99A], and M3135E11 [TgHDAC3T99I]) were treated with the indicated concentrations of FR235222 for 4 h and lysed. Total cell 
lysates were analyzed by immunoblot with anti-AcH4, anti-H4, anti-TgHDAC3, and anti–-tubulin antibodies as indicated.956 HDAC3-CONTROLLED DIFFERENTIATION IN APICOMPLEXA | Bougdour et al.
T99A-  or  T99I-encoding  mutations  (Fig.  2  B).  Resistant 
parasites were selected in the presence of 90 nM FR235222 
and emerged after transfection of the mutated but not WT 
TgHDAC3  fragments  (unpublished  data).  Clones  R20D9 
and R01E11 were selected after parasite transfection with the 
fragments containing the T99A- or T99I-encoding muta-
tions, respectively, and the sequences of their TgHDAC3 
gene were determined. The sequences from the R20D9 and 
R01E11 clones contained the T99A- or T99I-encoding mu-
tations,  respectively,  confirming  that  the  transfected  frag-
ments had replaced the endogenous TgHDAC3 in the clones 
(Fig. 2 B). Note that FR235222 treatment had no effect on 
DNA replication and IMC1-delineated daughter cells in the 
TgHDAC3T99A  and  TgHDAC3T99I  reconstructed  mu-
tants when compared with the WT parasites (Fig. 1 E and not 
depicted). We conclude that the T99A and T99I mutations 
in  TgHDAC3  are  each  sufficient  to  confer  resistance  to 
FR235222. Moreover, this provides additional support for 
the conclusion that the growth phenotype is not caused by 
the effect of FR235222 on the host cell.
Next, we compared resistance to FR235222 of the NEU-
mutagenized M190D4 and M3135C3 clones and of the re-
combinant  R20D9  and  R01E11  clones  (Fig.  2  C).  The 
M190D4 and the R20D9 clones that both harbor the T99A 
mutation displayed similar levels of resistance to FR235222 
(50 nM), although M190D4 was slightly more resistant than 
R20D9 in the presence of 60 nM FR235222. Of the clones 
carrying the T99I mutation, M3135C3 was significantly more 
resistant than R01E11, and both were slightly more resistant 
than the clones carrying the T99A mutation (Fig. 2 C). These 
data suggested that the NEU-mutagenized clones (M190D4 
and M3135C3) might contain additional FR235222 resistance 
mutations besides the TgHDAC3T99A and TgHDAC3T99I re-
constructed mutants, and that the latter might confer higher 
levels of resistance to FR235222 than TgHDAC3T99A. Thus, 
it is possible that FR235222 has a minor secondary mode of 
action or that alternative mechanisms of resistance exist. Of 
note, all mutated parasites grew less well than the WT in the 
absence of drug (Table S1), which could mean that there is a 
fitness cost for the parasite escaping the drug.
FR235222 inhibits HDAC3 activity in T. gondii
We next examined histone H4 acetylation in the resistant lines 
before and after exposure to FR235222 by immunoblot analysis 
hyperacetylation in the absence of host cells. In agreement 
with a direct action of FR235222 on the parasites, pretreat-
ment of HFF cells with 180 nM FR235222 for 12 h had no 
detectable effect on T. gondii growth after removal of the 
drug (unpublished data). In addition, immunoblot analysis 
showed that acetylation of histones H2B (K12 and K15) and 
H3K9 was not affected upon FR235222 treatment (Fig. S2), 
indicating that FR235222 specifically increases acetylation of 
the histone subunit H4.
FR235222 targets HDAC3 in T. gondii
The T. gondii genome (available from ToxoDB 5.0 at http://
toxodb.org/toxo/home.jsp) contains five putative nicotin-
amide adenine dinucleotide–independent HDAC-encoding 
genes (11). Given that T. gondii growth inhibition by FR235222 
correlates with increased levels of AcH4 (Fig. 1 F), the 
targeted enzymes are likely to function in the parasite nucleus. 
TgHDAC3, which acts on histone proteins (11) and localizes 
to the parasite nucleus (Fig. S3 A), appeared as a possible tar-
get of FR235222.
To further investigate the molecular basis of FR235222-
induced growth inhibition of T. gondii, we generated FR235222-
resistant parasite lines by chemical mutagenesis (see Materials 
and  methods).  Extracellular  tachyzoites  were  mutagenized 
using N-nitroso-N-ethylurea (NEU), and resistant parasites 
were selected in the presence of 90 or 135 nM FR235222 
(Table S1). Three resistant clones were isolated that grew 
normally in the presence of the drug. To determine whether 
these clones had mutated TgHDAC3, TgHDAC3 messenger 
RNA was amplified by RT-PCR and sequenced. Two clones, 
M190D4 and M3135C3, possessed T99A- and T99I-encoding 
mutations in exon 2 of TgHDAC3, respectively (Table S1). 
Interestingly,  the  T99  residue  is  part  of  a  two-residue 
(A98T99) extension specific to HDAC3 of Apicomplexan 
parasites (Fig. 2 A and Fig. S4). The third clone, M3135D8, 
grew normally in the presence of the drug but not in its ab-
sence, and contains a WT TgHDAC3 gene. The molecular 
basis  of  the  FR235222  resistance  and  dependence  of  this 
clone remains unknown.
To test whether the TgHDAC3 T99 mutations could ac-
count for T. gondii resistance to FR235222, mutations were 
introduced into the parental T. gondii RH strain. WT para-
sites were transfected with TgHDAC3 linear fragments en-
compassing an exon 2 that was either WT or contained the 
Table I.  Summary of EC50 of FR235222 on Apicomplexa and HFF primary host cells
Cells FR235222 EC50  
(nM ± SD)
Apicidin EC50  
(nM ± SD)
Pyrimethamine EC50  
(nM ± SD)
T. gondii RH WT 7.6 ± 0.6 15 ± 2 285 ± 61
T. gondii RH M190D4 62 ± 5 67 ± 16 300 ± 11
T. gondii Prugniaud 10 ± 1 – 195 ± 1
P. falciparum 8 ± 4 – –
N. caninum 8 ± 2 – –
HFFs 107 ± 18 165 ± 33 –
Apicidin (HDACi) and pyrimethamine (non-HDACi) were used as controls.JEM VOL. 206, April 13, 2009 
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DAC3 were produced by the WT and resistant lines, indicating 
that the mutations did not affect HDAC3 expression or stabil-
ity (Fig. 1 F). Therefore, the T99A and T99I mutations in 
TgHDAC3 likely affect the enzymatic activity on the histone 
(Fig. 1 F). In the absence of drug, basal AcH4 signals were 
somewhat  lower  in  the  R20D9  TgHDAC3T99A  line,  but 
higher in the R01E11 TgHDAC3T99I line, than in WT para-
sites. Immunoblotting also showed that similar levels of TgH-
Figure 2.  FR235222 induces acetylation of histones in T. gondii. (A) Sequence alignment of HDAC3 homologues in Apicomplexan parasites and 
other organisms. The region (from amino acids 122–141 of TgHDAC3) surrounding the point mutation identified in TgHDAC3-resistant mutants is shown. 
Rpd3 and HDLP are the HDAC homologues in Saccharomyces cerevisiae and the hyperthermophilic bacterium Aquifex aeolicus, respectively. Point muta-
tions identified in the T. gondii FR235222-resistant mutants are shown at the bottom. The multiple sequence alignment was generated by the Clustal 
alignment method using the BLOSUM scoring matrix (CLC Free Workbench, available at http://www.clcbio.com). Regions identical to the three proteins 
(light blue) and amino acids conserved exclusively in Apicomplexan parasites (red) are shown. Cp, Cryptosporidium parvum; Hs, Homo sapiens; Nc,  
N. caninum; Pb, P. berghei; Pf, P. falciparum; Tg, T. gondii. (B) Schematic representation of the exon (yellow boxes)–intron (dashed lines) structure of TgH-
DAC3. DNA fragments encompassing the point mutations T99A and T99I were PCR amplified using the primers indicated (arrows), and genomic DNA from 
the resistant mutants M190D4 and M3135C3 as DNA template, respectively. T. gondii RH strain was transformed with the resulting PCR-DNA fragments, 
and FR235222 was used to select transformants harboring the allelic replacement of TgHDAC3 on the T. gondii genome. The mutated residues T99A and 
T99I (red) are shown. The corresponding chromatograms are shown at the bottom. (C) Comparison of T. gondii WT and FR235222-resistant mutant line 
growth in the presence of different concentrations of FR235222. T. gondii RH WT strain resistant lines from the mutagenesis screen carrying the 
HDAC3T99A (M190D4) and the HDAC3T99I (M3135C3) mutations, and the reconstructed mutants by allelic replacement for HDAC3T99A (R20D9) and 
HDAC3T99I (R01E11) were grown in HFF monolayer until numerous parasitophorous vacuoles were observed with the resistant parasites (6 d). Means ± 
SD of cpm are shown (n = 2 experiments). (D) FR235222 is a direct inhibitor of TgHDAC3. Partially purified TgHDAC3-HA-FLAG (tag in the C-terminal 
position) from T. gondii parasites was assayed for HDAC activity in vitro as described in Materials and methods. Equivalent amounts of immunoprecipi-
tated protein were incubated with [3H]-labeled acetylated histones to determine enzymatic activity. Enzymatic activity is shown as a percentage of HDAC 
activity in the absence of inhibitor (set at 100%). Means ± SD are shown (n = 2 experiments).958 HDAC3-CONTROLLED DIFFERENTIATION IN APICOMPLEXA | Bougdour et al.
Figure 3.  Genome-wide analysis of the effect of FR235222 treatment on histone H4 acetylation in T. gondii tachyzoites. (A) Statistical analy-
ses of the AcH4 ChIP signal repartition across the T. gondii genome (see Materials and methods). The acetylated mark is more frequently enriched in both 
proximal and intergenic regions than within an internal gene region. (B) Diagram of the distribution of 369 FR235222 target genes (the up group) over 
Toxoplasma life-cycle stages, according to EST expression (tachyzoite, bradyzoite, and sporozoite). Numbers represent the percentage of genes that are 
either shared between two or three stages, or that are detected in a single stage. (C and D) The graphs indicate the fold enrichment of AcH4 over several 
FR235222 target genes. The signal from multiple closely spaced probes will often form a peak at or near the binding site. For each peak, the signals (se-
lected cutoff = 1.5) were summed ( ratio [log2]) over the distance of the peak (1,000 bp upstream the start codon). (E) A representative view of Toxo-
plasma ChIP-on-chip analysis. High resolution mapping of AcH4 location on chromosome IV (SRS9 locus) after FR235222 treatment versus mock DMSO. 
Each vertical bar represents the log2 signal ratio of the test sample signal divided by the input control signal. The x axis denotes the genomic position of 
each probe. A threshold of 1.5 was applied to each experiment. Green (intron) and blue (exon) boxes indicate ToxoDB 4.3 gene annotation. The data are JEM VOL. 206, April 13, 2009 
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visualized by Genobrowser software. (F and G) FR235222 treatment induces T. gondii Prugniaud strain differentiation. Intracellular parasites (12h after 
infection) were incubated in the presence of either alkaline growth media to induce in vitro differentiation or 40 nM FR235222 for 2–3 d. As a control, 
parasites were treated with 1 µM pyrimethamine. Bradyzoite-differentiated parasites were identified by IFA using an anti-P36 antibody. Percentages of 
SRS9/P36-positive parasitophorous vacuoles in each condition are shown. Means ± SD of P36+ vacuoles are shown (n = 2 experiments). P36 (SRS9) expres-
sion was analyzed by IFAs in intracellular tachyzoites (pH 7.2) and in bradyzoite-differentiated parasites in vitro (pH 8.2). Tachyzoites were grown in the 
presence of 0.1% DMSO or 0.01% ethanol for 24 h (pH 7.2) or for 2–3 d (pH 8.2), 40 nM FR235222 for 3 d, or 1 µM pyrimethamine for 2–3 d. Bars, 10 µm.
 
H4 substrate. Additionally, under 20-nM FR235222 treatment, 
the levels of AcH4 signals were increased approximately eight-
fold in the WT but were only increased approximately three-
fold and remained unchanged in the TgHDAC3T99A and 
TgHDAC3T99I  resistant  lines,  respectively.  These  data  are 
consistent with the hypothesis that the TgHDAC3 mutations 
confer resistance to the FR2352222-induced histone H4 hy-
peracetylation. Because these data indicate that AcH4s are na-
tive  substrates  for  TgHDAC3,  we  used  hyperacetylated 
chromatin and partially purified TgHDAC3-HA-FLAG en-
zyme to test its sensitivity to FR235222 in an in vitro HDAC 
assay. Fig. 2 D shows that FR235222 directly inhibits the en-
zymatic activity of TgHDAC3. Thus, these data are consistent 
with TgHDAC3 inhibition responsible for growth defects. 
Note that the pan-HDACi TSA and FR235222 have similar 
inhibition activities on purified TgHDAC3, which contrasts 
with their respective in vivo activities (Fig. 1 A). A simple ex-
planation could be that FR235222 has a higher ability to cross 
the host cell and parasitic membranes than TSA.
FR235222 affects histone H4 acetylation at bradyzoite-  
or stage-specific genes
Because FR235222 inhibits TgHDAC3 activity, we reasoned 
that the anti-TgHDAC3 property of FR235222 could be 
used to identify the genes that are controlled by TgHDAC3. 
To this end, we performed genome-wide AcH4 measure-
ments after FR235222 treatment (Fig. 3 and Table S2). Using 
ChIP and microarray hybridization (ChIP-on-chip assay), we 
analyzed the patterns of DNA-bound AcH4 after treatment 
of freshly lysed WT RH T. gondii with 40 nM FR235222 
for 4 h. Upon treatment with FR235222, H4 acetylation 
distribution was significantly altered across all 14 chromo-
somes, indicative of a large-scale nuclear reorganization event. 
Approximately 5% of the 7,817 predicted genes (available 
from ToxoDB 4.3) had increased H4 acetylation levels, de-
fining the Up group (369 genes; Table S2). The majority of 
AcH4 enrichment sites localized within 1 kb upstream of the 
gene start codon, with maximal enrichment immediately down-
stream of the transcription start site (TSS; Fig. 3 A and not 
depicted), possibly reflecting in some downstream effects at 
the transcriptional level of the genes affected.
Analysis of the genome-wide hyperacetylation pattern in-
duced by FR235222 led to three main observations. First, 
based on the abundance of stage-specific expressed sequence 
tags (ESTs), roughly one third of the genes in the Up group 
were found to be expressed exclusively in the bradyzoite 
and/or sporozoite stages (Fig. 3, B and C; and Table S2). 
Thus, when T. gondii type II Prugniaud strain was cultivated 
in the presence of 40 nM FR235222, growth was inhibited 
and 80% of the parasitic vacuoles expressed the bradyzoite-
specific antigen surface antigen glycoprotein–related sequence 
(SRS) 9/P36 at levels comparable to alkaline-stress parasites, 
which is known to induce stage conversion (Fig. 3, F and G). 
Very similar effects were observed by staining with the cyst-
specific CC2 mAb (unpublished data) (19, 20). A very weak 
induction  of  SRS9/P36  was  observed  in  parasites  treated 
with pyrimethamine (a non-HDACi compound) when com-
pared with FR235222-treated parasites; this indicates that the 
effect of FR235222 on SRS9/P36 expression is not solely 
caused by growth inhibition.
Then, we tested whether FR235222 was able to induce 
SRS9/P36 expression in the type I RH strain, which is char-
acterized by a poor ability to differentiate in bradyzoites in 
vitro. Fig. S6 A shows that RH strain intracellular tachyzoites 
grown in the presence of FR235222 expressed SRS9/P36 at 
higher levels than untreated parasites. Consistent with SRS9/
P36 up-regulation, nucleosomes at the level of the SRS9 lo-
cus were more acetylated in drug-treated parasites than in 
DMSO control (Fig. 3, C and E). However, SRS9 mRNA 
levels were not increased in response to HDACi treatment 
(unpublished data), suggesting that FR235222 might affect 
SRS9 expression in a more complicated fashion than solely 
through chromatin structure.
Given that mutations within TgHDAC3 confer resistance 
to FR235222, one could expect that induction of bradyzoite 
genes by HDACi’s would be abolished in the drug-resistant 
lines. To test this hypothesis, SRS9/P36 levels were moni-
tored by immunofluorescence analyses (IFAs) in the WT and 
TgHDAC3T99A mutant strains. Fig. S6 (A and B) shows that 
in the absence of HDACi’s, P36 expression became constitu-
tively expressed in the TgHDAC3T99A (R20D9) mutant strain 
compared with WT parasites. A very similar phenotype was 
observed in the TgHDAC3T99I (R01E11) mutant strain (un-
published  data).  Thus,  these  data  indicate  that  mutations 
T99A and T99I must affect the regulatory role of TgHDAC3 
on SRS9 expression.
However, many of the well-known bradyzoite-specific 
genes such as BAG1, LDH2, and ENO1 were not affected 
upon FR235222 treatment, showing that bradyzoite-specific 
genes are not controlled exclusively via histone H4 acetyla-
tion/deacetylation, as previously suggested (21). Second, al-
most half of the genes hyperacetylated by FR235222 have 
not been reported to be expressed at any of the parasite stages 
examined (Fig. 3 B), suggesting that they may be genes ex-
pressed at low levels or at an intermediate stage not covered 
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the mode of action of a novel compound, FR235222, that 
efficiently inhibits parasite growth in vitro. We found that 
point mutations within TgHDAC3 were sufficient to decrease 
the sensitivity of T. gondii parasites to FR235222 or apicidin 
(Fig. 1 A and not depicted), thus providing genetic evidence 
that TgHDAC3 is the drug-targeted enzyme.
The basis for selective inhibition of HDACi’s is one of 
the  key  unsolved  questions  concerning  these  compounds. 
The active site of class I and II HDAC is characterized by a 
structurally conserved catalytic core containing a divalent zinc 
cation. Crystallographic structures of the human HDAC7 
(23) and HDAC8 (24, 25), along with the bacterial HDAC-
like protein (HDLP) (26), showed that the mechanism of in-
hibition by HDACi’s relies on the delivery of a zinc binding 
group to the bottom of a narrow active site pocket formed by 
loops L1 to L7 (Fig. S4) (26). Based on sequence homology, 
mutations in TgHDAC3 (T99A and T99I) conferring resis-
tance to FR235222 localize to the L2 loop of HDLP, where 
the residue Y91 localized at the rim of the active site contacts 
the cognate HDACi (TSA; Fig. 2 A and Fig. S4) (26). Struc-
tural data of HsHDAC8 pointed out the role of the residue 
D101 in both substrate and HDACi recognition; HsH-
DAC8D101A mutated enzyme was inactive on protein sub-
strates and binding efficiency to hydroxamate inhibitor was 
decreased (25). Given that D101 is localized in the vicinity of 
T99 of TgHDAC3, these data further strengthen the hypoth-
esis of a direct inhibition of TgHDAC3 by FR235222 and 
are consistent with a role of T99 in the interactions with cy-
clopeptide inhibitors. T99A and T99I change amino acid 
polarity; it is therefore tempting to speculate that polar inter-
actions at the rim of the active site support the binding to 
HDACi’s, as proposed by Vannini et al. (25). We predict that 
the binding efficiency of HDACi’s to TgHDAC3 would be 
diminished in the T99A and T99I mutated versions of TgH-
DAC3. However, an effect of these mutations on the regula-
tion and/or activity of TgHDAC3 compensating the decrease 
in HDAC activity caused by drug inhibition cannot be ex-
cluded. In summary, the data presented in this study show 
the unexpected role of the Apicomplexa-conserved T99 resi-
due for the resistance to cyclopeptide HDACi’s.
Gene expression in Apicomplexan parasites is consider-
ably dynamic, with large numbers of mRNAs exclusively ex-
pressed  in  a  single  developmental  stage.  In  P.  falciparum, 
microarray studies revealed a remarkably tight regulatory pro-
cess that generates a continuous cascade of gene expression. 
Most genes are induced maximally at a time when they are 
presumably required for the parasite, after which the genes are 
down-regulated, leading to the hypothesis of the “just-in-time” 
manufacturing process (27). Similar observations have been 
made in T. gondii, where the primary developmental transi-
tions are also accompanied by temporal changes at the level 
mRNAs from genes that are dispersed across all chromosomes 
(5). The details of how the expression of genes is controlled 
in these parasites have not been determined yet, although al-
terations in chromatin structure have been associated with 
changes in expression (2, 28). Indeed, it is now becoming 
affected functionally and structurally related genes (Fig. 3,   
C and D). For example, the 13 genes encoding for the SRS 
antigen family, which are scattered over seven different chro-
mosomes,  were  all  hyperacetylated  in  FR235222-treated 
parasites. This indicates that histone acetylation induced by 
FR235222 can target physically unlinked but functionally re-
lated genes in the parasite genome.
Next, we tested whether FR235222 was capable of in-
ducing expression of the genes that have hyperacetylated his-
tone H4. For this, we used 20.m00351 as a target gene, 
which encodes a bradyzoite-specific heat shock-related pro-
tein (Fig. 4 A) (22). Indeed, the 20.m00351 mRNA levels 
accumulated in FR235222-treated parasites, indicating that 
FR235222 can influence the expression of bradyzoite-spe-
cific genes at the transcriptional level (Fig. 4 C). Induction of 
20.m00351 transcripts by HDACi treatment was similar to 
those observed in alkaline-induced bradyzoites (Fig. 4 C). In 
agreement with this, ChIP-on-chip assays showed that his-
tone H4 was hyperacetylated at the 20.m00351 promoter re-
gion  upon  FR235222  treatment  (Fig.  4  A),  whereas  the 
AcH4 levels remained unaffected by the drug in the neigh-
borhood of the DHFR encoding gene that is steadily ex-
pressed in tachyzoite and bradyzoite parasites (Fig. 4 B). ChIP 
assays followed by semiquantitative PCR (scanning ChIP) 
confirmed that nucleosomes upstream of 20.m00351 were 
hyperacetylated in FR235222-treated parasites (12-fold in-
duction; Fig. 4 D), whereas AcH4 signals upstream of the 
control DHFR gene were not modified in treated parasites 
(Fig. 4 D). Therefore, it is likely that histone H4 acetylation 
is the primary control mechanism of 20.m00351 transcrip-
tion in response to FR235222 treatment.
FR23522-resistance mutations in TgHDAC3 decrease  
the enzyme activity
Finally, we examined by scanning ChIP assays the AcH4 lev-
els in the 5 regulatory region of the 20.m00351 locus in the 
WT and in the TgHDAC3T99A and TgHDAC3T99I resistant 
lines in the presence or absence of FR235222. As expected, 
in the WT, AcH4 levels at the 20.m00351 locus were in-
creased 12-fold in the presence of the drug, whereas in the 
TgHDAC3T99A resistant line no difference in the AcH4 levels 
were noticed in the presence or absence of the drug (Fig. 4 D). 
However, in the absence of the drug, the AcH4 levels of the 
resistant lines were approximately threefold higher than those 
of the WT (Fig. 4 B). This showed that the T99A and T99I 
mutations also affect the basal activity of TgHDAC3 at the 
20.m00351 locus. This is in agreement with our earlier find-
ing that resistant parasites constitutively express SRS9 in the 
absence of drug treatment (Fig. S6).
DISCUSSION
Compared with the widespread use of HDACi’s in the can-
cer field, much less is known about the effects of these com-
pounds on Apicomplexan parasites. In this study, we provide 
new insight into the effects of HDACi’s on Plasmodium spe-
cies, T. gondii, and N. caninum, with the characterization of JEM VOL. 206, April 13, 2009 
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also functionally and structurally related genes (Fig. 3, C and D). 
Moreover, the long-range histone acetylation pattern induced 
by FR235222 expands over linked families of genes, suggest-
ing once more a common transcriptional regulation through 
increasingly clear that acetylation balance is greatly altered 
during parasite differentiation. How these changes are regu-
lated at the molecular level remains unknown. Our data indi-
cate that FR235222-mediated histone hyperacetylation affects 
Figure 4.  TgHDAC3 is a regulator of T. gondii differentiation. (A) High resolution ChIP-on-chip mapping of AcH4 location on chromosome VIIa 
(20.m00351 locus) after FR235222 treatment versus mock DMSO, as described in Fig. 3 E. (B) High resolution ChIP-on-chip mapping of AcH4 location 
on chromosome XII (DHFR locus) after FR235222 treatment versus mock DMSO, as described in Fig. 3 E. (C) FR235222 treatment induced the expression 
of the gene 20.m00351. mRNA levels of 20.m00351 were analyzed by RT-PCR in intracellular tachyzoites (pH 7.2) and in bradyzoite-differentiated para-
sites in vitro (pH 8.2). Tachyzoites were grown in the presence of 0.1% DMSO for 24 h (pH 7.2) or for 2–3 d (pH 8.2), or 40 nM FR235222 for 3 d. Lanes 
1–4 and lanes 5–8 represent fourfold serial dilutions of the first-strand cDNA from parasites treated with 0.1% DMSO (pH 7.2 and 8.2) and 40 nM 
FR235222. -Tubulin mRNA are expressed equally in each set of experiments and are presented as a control (n = 3 experiments). (D) Scanning ChIP 
experiments showing the effects of FR235222 on AcH4 levels in the presence of the TgHDAC3 WT, TgHDAC3T99A, and TgHDAC3T99I alleles at the pro-
moter region of the bradyzoite-specific gene 20.m00351. ChIP analysis and quantification were performed as described in Materials and methods. The 
ratios of 20.m00351 and control DHFR signals present in input samples were used to calculate the relative precipitated fold enrichment shown below 
each lane (n = 3 experiments). A representative set of data is shown.962 HDAC3-CONTROLLED DIFFERENTIATION IN APICOMPLEXA | Bougdour et al.
The potential antiparasitic activity of HDACi’s has been 
reported before by others (13, 32–34), but obtaining drugs 
selective of Apicomplexan parasites is the major challenge. 
We observed that FR235222 inhibits parasite proliferation 
without affecting dramatically normal human host cells; para-
sites are 10 times more sensitive to FR235222 than HFF 
cells in our in vitro conditions, thus revealing a certain speci-
ficity of action of FR235222 toward parasites (Fig. 1 A and 
Fig. S7). Though FR235222 is relatively nontoxic to primary 
host human cells (Fig. S7) (16), an increase in AcH4 levels in 
human cells was observed at high concentrations (1 µM) of 
FR235222, indicating that this compound is somehow active 
on one or multiple mammalian HDACs (17). Possibly, the 
mammalian enzymes inhibited are not involved in essential 
biological functions, at least in our conditions. Given that no 
comparative  analyses  of  mammalian  versus  Apicomplexan 
HDACs are currently available, no clear-cut conclusion about 
the isoenzyme selectivity of FR235222 can be drawn. Muta-
tions in TgHDAC3 were at least sufficient to confer resistance 
to FR235222, and the mutated residue T99 of TgHDAC3 is 
conserved exclusively in the homologous enzymes present in 
all Apicomplexan parasites; therefore, an attractive model is 
that sensitivity to cyclopeptide HDACi’s is carried by specific 
residues present only on parasitic HDACs but absent in mam-
malian homologues. Thus, a selective inhibition of Apicom-
plexan HDAC provides an elegant and novel way to interfere 
with parasite proliferation. Although it has been shown that 
FR235222 is bioactive in animal models (35, 36), a direct 
demonstration of its effectiveness in vivo against T. gondii re-
mains to be performed.
MATERIALS AND METHODS
Parasite strains, cell culture, and in vitro bradyzoite differentiation. 
The parasite strains used in this study are the following: the T. gondii type I 
RH strain that has lost the ability to complete the two-host life cycle, the 
T. gondii type II Prugniaud strain that is capable of robust bradyzoite differen-
tiation, and the T. gondii type III CTG strain. All T. gondii and N. caninum 
strains were maintained by serial passage in HFF monolayer under tachyzoite 
conditions in DMEM (Invitrogen) supplemented with 10% (vol/vol) FBS 
(Invitrogen). T. gondii type II Prugniaud strain was maintained under tachyzo-
ite conditions in DMEM supplemented with 10% (vol/vol) FBS and 25 mM 
Hepes buffer, pH 7.2. To induce in vitro bradyzoite differentiation, extracel-
lular tachyzoites were allowed to invade HFF cells for 16 h, and the culture 
medium was removed and replaced by RPMI1640 supplemented with 1% 
FBS and 50 mM Hepes buffer, pH 8.2. After 2–3 d of culture in alkaline me-
dium, bradyzoite induction was assessed for P36 expression by IFA.
Mutagenesis. Parasites were chemically mutagenized according to a modi-
fication of a previously published protocol (37). 107 tachyzoites (freshly emerged 
from their host cells) were incubated at 37°C for 2 h in serum-deficient 
minimal essential medium containing 150 µg/ml NEU (diluted from a 1% 
stock solution in PBS). Parasites were washed two times and were allowed to 
recover in a fresh T25 flask of HFF monolayer in the absence of drug for 3 d. 
Released tachyzoites were then inoculated into fresh cell monolayers in me-
dium containing 90 nM FR235222 and incubated until viable extracellular 
tachyzoites emerged 20 d later. Surviving parasites were passaged once more 
under continued FR235222 treatment and cloned by limiting dilution. Three 
cloned mutants (M190D4, M3135C3, and M3135D8) were isolated. TgH-
DAC3 open reading frame (orf) was amplified by RT-PCR using primers PstI-
HDAC1-PCR3  (5-AACTGCAGGATCGGAACCTTTTGGTCTCTG-3) 
chromatin structure (Fig. 3 E and Fig. S5 C). It is possible, 
then, that the loci containing clustered homologous genes 
are generally regulated by enhancer regions that impose 
stricter control of initiation than typically observed at other 
genes. Interestingly, when ChIP-on-chip data of AcH4 
were compared with ChIP-on-chip data obtained using an 
anti-Myc–SET8 antibody (29), we noticed broad DNA re-
gions with low levels of histone acetylation embedded into 
heterochromatic  regions.  The  histone  methylase  SET8  is 
known to contribute to marking silent heterochromatic do-
mains in Apicomplexan genomes by methylating H4K20 (29). 
It is noteworthy that FR235222 is unable to spread the 
hyperacetylation over the constitutive heterochromatin do-
mains marked by SET8 (Fig. S5 D). Thus, the regions affected 
by  FR235222  seem  to  correspond  to  facultative  hetero-
chromatin; constitutive heterochromatin cannot be hyper-
acetylated, probably because of methylation of histone H4 
at lysine 20.
In this study, we provide direct evidence that the HDAC3 
family plays a role in gene expression, differentiation, and 
cell-cycle control. Drug inhibition of TgHDAC3 prevents the 
formation of the daughter cells. Moreover, parasites treated 
with low doses of FR235222 are committed to differentiate 
into bradyzoites. This is consistent with the observations that 
during bradyzoite conversion a transient slowing of S phase 
leads to mature bradyzoites, which possess a uniform genome 
content (1N DNA) consistent with cell-cycle arrest in G1/
G0 (30, 31). Moreover, drug inhibition of TgHDAC3 and 
parasites mutated at TgHDAC3 (TgHDAC3T99A and TgH-
DAC3T99I) lead to the expression of the bradyzoite marker 
SRS9 (Fig. S6). These data support previous observations 
that TgHDAC3 plays a role in the regulatory pathway driv-
ing parasite conversion (11).
A recent study indicated that a strong inducer of bradyzo-
ite differentiation known as compound 1 up-regulated the 
transcription of bradyzoite-specific genes (21). By comparing 
the  effect  of  FR235222  on  nucleosome  acetylation  levels 
with the effect of compound 1 on transcript levels, we could 
determine that a core set of genes is common to bradyzoite 
differentiation induced by compound 1 and FR235222, as 
well as sets of genes that are specifically affected by each 
molecule (Fig. S5 A and Table S2). This further indicates 
that FR235222 affects the regulation of bradyzoite-specific 
genes at an epigenetic level (Table S2). However, with the 
exception of the B-NTPase gene (42.m03416), none of the 
well-known bradyzoite-specific genes (e.g., BAG1, LDH2, 
and ENO1, available from ToxoDB under accession nos.   
55.m00009, 80.m00010, and 59.m03411, respectively), which 
are strongly induced by compound 1, were affected upon 
FR235222 treatment. One explanation could be that this 
group of genes is regulated by a different mechanism than 
through histone H4 acetylation or deacetylation, as previously 
suggested (21). However, whether these reflect differences in 
the effect of compound 1 and FR235222 or discrepancies 
between histone H4 acetylation levels and transcriptional ac-
tivity has not been investigated further.JEM VOL. 206, April 13, 2009 
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Mowiol 4-88 [wt/vol], 12% glycerol [vol/vol]), and images were acquired 
with a fluorescence microscope (Axioplan 2; Carl Zeiss, Inc.) equipped with 
40  and  100×  objectives  and  a  charge-coupled  device  camera  (Axiocam 
MRm; Carl Zeiss, Inc.) coupled to Axiovision 4.5 software (Carl Zeiss, 
Inc.). U. Gross (University of Göttingen, Göttingen, Germany), W. Bohne 
(University of Göttingen, Göttingen, Germany), G.E. Ward (University of 
Vermont, Burlington, VT), and J.F. Dubremetz (Centre National de la 
Recherche Scientifique, Montpellier, France) provided antibodies.
Isolation of T. gondii [3H]acetyl-labeled histones. T. gondii (type I 
RH strain) extracellular tachyzoites (3 × 108 parasites) were resuspended 
in fresh medium containing 2.5 mCi sodium [3H]acetate (0.1 Ci/mmol; 
PerkinElmer) and 10 mM sodium butyrate. Parasites were incubated at 
37°C for 1 h. Parasites were then washed in cold PBS and resuspended in 
700 µl RSB buffer (10 mM Hepes [pH 8], 10 mM KCl, 1.5 mM MgCl2, 
0.5% NP-40 [vol/vol], 0.5 mM dithiothreitol [DTT], and 1 mM PMSF). 
Parasites were lysed using a dounce (tight plunger) and lysate was centrifu-
gated at 10,000 g for 10 min at 4°C. To acid extract the histones, the nu-
clear pellet was resuspended in 0.2 ml 5 M MgCl2 and 0.2 ml 0.8 M HCl 
was added. The mixture was incubated overnight at 4°C. Insoluble material 
was removed by centrifugation at 16,000 g for 10 min at 4°C, and the solu-
ble fraction containing radiolabed histones was precipitated with 33% TCA 
final concentration. Precipitated histones were washed twice with ice-cold 
acetone and resuspended in 100 µl of water. Protein concentration was de-
termined by Bradford assay using BSA as a standard, and specific activity 
was determined as 154.5 cpm/µg.
HDAC assay. TgHDAC3-HA-FLAG was partially purified from transgenic 
extracellular  tachyzoites  expressing  TgHDAC3-HA-FLAG  ectopically,  as 
previously described (11). Parasite pellets (3 × 109 tachyzoites) containing 
TgHDAC3-HA-FLAG recombinant proteins were resuspended in 15 ml of 
lysis buffer (20 mM Tris-HCl [pH 8], 500 mM KCl, 1.5 mM MgCl2, 0.2 mM 
EDTA, 0.5 mM DTT, 20% glycerol [vol/vol], 0.5% NP-40 [vol/vol],1 mM 
PMSF, and protease inhibitor cocktail [Roche]). Parasites were lysed using a 
dounce (tight plunger), and lysate was centrifugated at 20,000 g for 30 min at 
4°C. The soluble fraction was applied to an anti-FLAG M2 affinity gel col-
umn (500 µl; Sigma-Aldrich) equilibrated with lysis buffer. The column was 
washed with a 40-column volume of lysis buffer and the beads–anti-FLAG–
TgHDAC3–HA–FLAG matrix was resuspended in 500 µl HDAC buffer 
(50 mM Tris-HCl [pH 8], 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2). 50-µl 
aliquots of this matrix were used as a source of TgHDAC3-HA-FLAG in the 
HDAC assays. Reaction mixtures were assembled in a 100-µl final volume of 
HDAC buffer containing 1 mg/ml BSA, a 50-µl aliquot of the HDAC-bead 
matrix described, and 0–1,000-nM final concentrations of HDACi’s (TSA 
and FR235222). The mixtures were incubated at room temperature for 
15 min to allow HDACi–HDAC complex formation. HDAC reactions were 
initiated by the addition of [3H]acetyl-labeled histones (3,708 cpm) as the 
substrate. After 1 h of incubation at 37°C, the reactions were stopped by the 
addition of 10 µl of 11 M HCl. The released [3H]acetic acid was extracted 
with 1 ml ethyl acetate. 900 µl of the solvent layer was then mixed with 5 ml 
of toluene scintillation solution, quantitated by scintillation counting, and 
used as a measure of HDAC activity.
Electrophoresis and immunoblot analysis of proteins. Whole-cell ex-
tracts were prepared as follows: 107 extracellular parasites (needle passed, 
and filtered using a 3-µm nucleopore membrane) were lysed in 50 µl of lysis 
buffer (10 mM Tris-HCl [pH 6.8], 0.5% SDS [vol/vol], 10% glycerol [vol/
vol], 1 mM EDTA) and sonicated. Protein concentration was determined by 
using the Bradford protein assay kit (Bio-Rad Laboratories) and BSA as a 
standard. A total of 50 µg of protein per sample was analyzed by using Nu-
PAGE 4–12% Bis-Tris polyacrylamide gels with MES-SDS running buffer 
(Invitrogen), transferred onto nitrocellulose membrane (Hybond-ECL; GE 
Healthcare)  or  polyvinylidene  fluoride  membrane  (Immobilon-P;  Milli-
pore), and probed with a 1:1,000 dilution of an anti-AcH4 antiserum (AcH-
4K5K8K12K16; Millipore), a 1:500 dilution of an anti–histone H4 antiserum 
and HDAC1-PCR5-BamHI (5-CGGGATCCGCGCTCAGTGCGCT-
GCGCAAGC-3). The resulting PCR products were cloned into pCRII-
TOPO cloning vector using the TOPO TA cloning kit (Invitrogen)   
and sequenced.
Transformation and selection of FR235222-resistant transformants. 
DNA fragments containing the DNA sequences flanking the codon coding 
for the residue T99, and the mutated residues T99A and T99I of TgHDAC3 
were generated by PCR amplification of the genomic DNA of the WT RH 
strain, M190D4, and M3135C3 resistant lines, respectively. Primers HD1-
oligo2-PCR5 (5-GACCTCTACAAACATATGGTGAGTG-3) and HD1-
oligo3-PCR3 (5-GATACACGTCCACGCACTTGGTGATG-3) amplify 
the TgHDAC3 sequence from nucleotides 133 to 1930 of the TgHDAC3 
orf, producing a PCR product of 1,798 bp (Fig. S4).
Approximately 107 tachyzoites (RH WT strain) were transfected with 6 µg 
of linear DNA fragments by using electroporation parameters established pre-
viously (38). After electroporation, parasites were allowed to recover over-
night in HFF monolayer in the absence of drug, and parasites were selected in 
90 nM FR235222; resistant parasites were single-cell cloned and the TgH-
DAC3 DNA sequence was determined as described. Note that transfection of 
the type II Prugniaud strain was unfruitful in providing resistant parasites.
Proliferation assays. The extent of the growth of T. gondii in monolayer 
cultures was determined by measuring the incorporation of [3H]uracil into 
acid-precipitable material. Human fibroblasts were grown to confluence in 
24-well plates and infected with 103 T. gondii tachyzoites per well in the ab-
sence or the presence of FR235222. After 72 h, the culture was washed with 
PBS to remove noninvading parasites and replenished with fresh medium 
containing 5 µCi [3H]uracil/well. After 4 h, the monolayers were washed 
with PBS to remove nonincorporated [3H]uracil, and the remaining materi-
als were solubilized in 500 µl of lysis/scintillation solution (Optiphase Super 
Mix; Perkin Elmer). The radioactivity was quantified by liquid scintillation 
spectrometry using a multidetector liquid scintillation counter (MicroBeta 
TriLux; Perking Elmer). EC50 has been determined according to nonlinear 
regression analysis using Prism 5 software (GraphPad Software, Inc.).
Quantitative assessment of the antimalarial activity of FR235222 was per-
formed as previously described (39) on P. falciparum clones 3D7 and Dd2, ex-
cept that the parasites were in contact with the drug for 48 and 20 h for the 
asynchronous 3D7 and Dd2 cultures and plasmion-enriched 3D7 schizonts, 
respectively. EC50 has been determined according to nonlinear regression analy-
sis using HN-NonLin V1.1 software (available at http://malaria.farch.net).
Synchronized cultures of P. berghei GFP@hsp70 ANKA strain were 
performed as previously described (40). Cultures were grown in the presence 
of DMSO alone or with FR235222 added at 5, 11, and 22 h. Cultures were 
examined at 5, 11, 22, and 24 h after Giemsa staining and by FACs after 
DNA staining with Hoechst 33258 (Invitrogen).
The effect of HDACi’s on mammalian host cell proliferation was as-
sayed on nonconfluent HFF monolayers treated with FR235222 or TSA. 
Cell proliferation was quantified using CellTiter Aquous Phase kit (Pro-
mega). EC50 has been determined according to nonlinear regression analysis 
using Prism 5 software.
Immunofluorescence microscopy. Infected HFFs grown on coverslips 
were washed in PBS and fixed/permeabilized for 20 min at room tempera-
ture with PBS containing 3% (vol/vol) formaldehyde and 0.2% Triton   
X-100 (vol/vol). Blocking was performed with PBS containing 5% FBS and 
5% goat serum for 1 h at room temperature. Samples were incubated in PBS 
containing 1% FBS with the primary antibodies indicated in the figures 
(1:1,000 dilutions of anti-AcH4 antiserum [Millipore], anti-P36 monoclonal 
mouse antibodies, and anti-IMC1 monoclonal mouse antibodies), followed 
by the secondary antibodies goat anti–mouse IgG coupled with Alexa Fluor 
488 and goat anti–rabbit IgG coupled with Alexa Fluor 568 (Invitrogen) at 
a 1:1,000 dilution each in PBS–1% FBS. Nuclei of host cells and parasites 
were stained for 10 min at room temperature with Hoechst 33258 at 2 µg/
ml in PBS. After four washes in PBS, coverslips were mounted on a glass 
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EDTA-free cocktail [Roche]), and DNA was digested for 4 min at 37°C by 
2 U/ml MNase. Digestion was stopped with 20 mM EDTA, and chromatin 
was recovered in the soluble fraction after centrifugation at 10,000 g at 4°C; 
this constituted the S1 fractions. Pelleted materials were resuspended in di-
alysis buffer (1 mM Tris-HCl [pH 7.8], 0.2 mM EDTA) containing 1 mM 
PMSF and protease inhibitor cocktail and were dialyzed overnight at 4°C 
against the same solution. Dialyzed materials were then centrifuged and su-
pernatants were harvested; this constituted the S2 fractions. For ChIPs, frac-
tions S1 and S2 were pooled and DNA quality was verified by electrophoresis 
on 2% agarose gels; oligonucleosome ladders of 100–1,000 bp were obtained. 
The histone–DNA complexes were immunoprecipitated with anti-AcH4 
antibodies  according  to  NimbleGen’s  protocol  (available  at  http://www 
.vmrf.org/researchcenters/gene-chip/chromatin_immunoprecipitation.pdf). 
In brief, sheep anti–rabbit IgG Dynabeads (1 ml per reaction; Invitrogen) 
were incubated with 200 µl anti-AcH4. Dynabeads (beads–IgG–anti–AcH4 
complexes) were then washed with 5 mg/ml BSA in PBS and incubated with 
500 µg chromatin. Dynabead complexes were washed twice in RIPA buf-
fer (50 mM Hepes [pH 8], 1 mM EDTA, 1% NP-40 [vol/vol], 0.7% deoxy-
cholate [wt/vol], 0.5 M LiCl) containing protease inhibitor cocktail, followed 
by two washes in 1× TE buffer (10 mM Tris-HCl [pH 8], 1 mM EDTA). 
Bound chromatin was eluted in 250 µl of elution buffer (10 mM Tris-HCl   
[pH 8], 1 mM EDTA, 1% SDS [vol/vol]). Histone–DNA cross-links were re-
versed by incubation at 65°C overnight in the presence of 150 mM NaCl and 
was phenol-chloroform purified. Isolated DNA samples (input and immuno-
purified DNA) were arrayed on custom synthetic oligo arrays (387,000 
features per array, 46–50mer oligos; NimbleGen) according to the manufac-
turer’s protocol, and data analysis was performed as previously described (29). 
The data are visualized by Genobrowser software (available at http://www 
.genostar.com/en/genostar-software/genomic-analysis-tools/genobrowser.html). 
The raw data discussed in this paper have been deposited in the Gene Ex-
pression Omnibus under accession no. GSE15241. The genome-wide data 
have been integrated into the Toxoplasma database (ToxoDB).
For scanning ChIP assays, freshly released tachyzoites (2 × 108 at 
2 × 107 parasites/ml) were fixed as described above. Immunoprecipitated 
DNA was subjected to PCR analysis. 20.m00351 was amplified by PCR 
using primers 20.m00351_B F (5-AGCTGTGCCGTTTGCGTGCCG-3) 
and 20.m00351_B R (5-TCCTACACCACGGGCGATTC-3). DHFR 
was amplified using primers DHFR_B F (5-CAAACCCGAGAAAAAGA-
AACG-3) and DHFR_B R (5-TGCTGTTCGCAGTCCCAGTAG-3). 
All PCR reactions were performed in a 50-µl final volume, starting with 
4 min at 94°C and followed by 30–35 cycles (depending on the region being 
amplified) of 94°C, 55°C, and 72°C (30 s each), with a final elongation of 
10 min at 72°C. PCR products were separated on 2% agarose gels and ana-
lyzed using ImageJ software (available at http://rsbweb.nih.gov/ij/). Note 
that no PCR products were detected when DNA samples were assayed by 
ChIP using beads coupled with anti-GST antibodies instead of anti-AcH4 
antibodies, indicating that our immunoprecipitated DNA fragments were 
specific to anti-AcH4 antibodies.
Statistical analyses of AcH4 ChIP-chip signal repartition across the 
genome. Statistical analyses of the ChIP signal repartition were performed 
with the R package software, as previously described (29). The chromo-
somal regions were clustered into three main DNA sequences: the coding 
sequence (CDS; specified here as “gene”), the proximal region (1,000 bp 
upstream and downstream of each CDS), and the intergenic region. The en-
richment within these three regions (“observed proportion”) were com-
pared with what should be expected if signals have a uniform repartition 
(“theoretical proportion”). The test is a classical proportion test. For each 
chromosome, we computed the following formula: C is the chromosome 
size, L is the region size, NC is the number of signals in the chromosome, 
NL is the number of signals in the region, PC is the theoretical proportion, 
and P is the observed proportion. The computed value is assumed to follow 
the standard normal distribution when the two conditions CV1 = NC × PC 
and CV2 = NC × (1  PC) are at least equal to 5. When this is the case, the 
value |z| = 1.96 has a probability of 0.05 to be exceeded.
(H4; Millipore), a 1:1,000 dilution of an antiacetyl–histone H2B antiserum 
(AcH2BK12K15; Abcam), a 1:1,000 dilution of an anti-H3 antiserum (H3; 
Abcam), a 1:1,000 dilution of an antiacetyl–histone H3K9 antiserum (AcH3K9; 
Abcam), a 1:2,000 dilution of a monoclonal anti–-tubulin antibody (Sigma-
Aldrich), and a 1:1,000 dilution of an anti-TgHDAC3 antibody (see Materi-
als and methods). The blots were developed with the SuperSignal West Pico 
Chemiluminescent Substrate kit (Thermo Fisher Scientific).
Anti-TgHDAC3  antibodies.  Antiserum  against  TgHDAC3  was  pro-
duced by Eurogentec using the Super Speedy immunization protocol and 
peptide  #10  (C+DFEDMADRDQKVPI-COOH).  Specific  antibodies 
were affinity purified against peptide #10. For immunoblot analysis and 
IFAs, purified antibodies were used at 1:500 dilutions. IFAs confirmed that 
the majority of TgHDAC3 signals are localized to the nucleus of the intra-
cellular tachyzoites (Fig. S1 A). Immunoblotting using 30 µg of proteins/ 
lane revealed a signal at the expected size (50 kD) for TgHDAC3 (Fig. S1 B). 
Immunoblot analysis of the RH strain transfected with Pgra1-TgHDAC3-
HA-FLAG (11) revealed the presence of two bands: the first one corre-
sponding to the signal at 50 kD (endogenous TgHDAC3) was also detected 
in the WT parasites, and a second signal with a higher molecular mass (3 
kD) that corresponds to the addition of the HA-FLAG tags in the C-termi-
nal position of the protein.
Semiquantitative RT-PCR. mRNA levels of 42.m03416, 20.m00351, and 
-tubulin (583.m00022) were analyzed by RT-PCR in FR235222-treated 
parasites and in bradyzoites induced in vitro. T. gondii type II Prugniaud strain 
was cultured under tachyzoite conditions in DMEM supplemented with 10% 
(vol/vol) FBS and 25 mM Hepes buffer, pH 7.2. To induce in vitro bradyzo-
ite differentiation, extracellular tachyzoites were allowed to invade HFF cells 
for 16 h, and the culture medium was removed and replaced by RPMI 1640 
supplemented with 1% FBS and 50 mM Hepes buffer, pH 8.2. Parasites were 
allowed to differentiate for 2 d of culture in alkaline medium. To moni-
tor the effect of FR235222 on mRNA levels, extracellular tachyzoites were   
allowed to invade HFF cells for 16 h under tachyzoite growth conditions 
(pH 7.2), and 40 nM FR235222 was added to the medium. After 3 d of 
growth in the presence of 40 nM FR235222 or 24 h of growth in the pres-
ence of 0.1% DMSO (mock experiment), infected HFF monolayers contain-
ing intracellular parasites were scraped from culture flasks, needle passed, and 
filtered using a 3-µm nucleopore membrane to separate parasites from host-
cell debris. Parasites were resuspended in 1 ml TRIzol reagent (Invitrogen). 
All subsequent purification steps were performed according to the manufac-
turer’s instructions. Concentrations of RNA samples were determined by 
measuring the OD value at wavelength 260. RT reactions were performed 
using 5 µg of total RNA, 100 µM of an oligo-(dT)25-(N)7 primer, and 400 
U SuperScript III RT (Invitrogen). RT-PCR was performed according to 
the manufacturer’s instructions. cDNA of 42.m03416, 20.m00351, and -
tubulin were amplified by PCR using DyNAzyme EXT DNA Polymerase 
(Finnzymes) and 1 µl of different dilutions of the cDNA products as DNA 
template. 20.m00351 was amplified using primers 20.m00351 F1 (5-TGT-
ATGAAGGCGATTCGTGC-3) and 20.m00351 R1 (5-ACCTTCTG-
GATGTCAGTCTC-3); -tubulin was amplified using primers -TUB-F 
(5-GTTATCAGCATCCACGTCGG-3) and -TUB-R (5-CTTCTT-
GCCGTAGTCAACAGAC-3). PCR products were resolved via 1% aga-
rose gel electrophoresis and visualized by ethidium bromide staining.
ChIP assay. Freshly released tachyzoites were needle passed and filtered 
using a 3-µm nucleopore membrane. Parasites were resuspended into fresh 
DMEM supplemented with 10% (vol/vol) FBS and 25 mM Hepes buffer, 
pH 7.2. Parasites were incubated in the presence of 40 nM FR235222 and 
0.1% DMSO for 4 h at 37°C with 5% CO2. For ChIP-chip experiments, 
freshly released tachyzoites (5 × 109 at 12 × 107 parasites/ml) were fixed 
for 15 min in 1% formaldehyde. An increase in AcH4 signals was verified by 
immunoblotting to verify that FR235222 treatment was effective. To pre-
pare chromatin samples, fixed parasites were lysed in MNase buffer (0.32 M   
sucrose, 50 mM Tris-HCl [pH 7.8], 4 mM MgCl2, 3 mM CaCl2, 100 mM 
NaCl, 0.25% NP-40 [vol/vol], 5% glycerol [vol/vol], protease inhibitor JEM VOL. 206, April 13, 2009 
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